


Antitumor agent-86

Cat. No.:	HY-152774
CAS No.:	2907704-65-6
Molecular Formula:	C ₂₉ H ₃₁ N ₅ O ₂ S
Molecular Weight:	513.65
Target:	Akt; PI3K
Pathway:	PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC ₅₀ value of 2.62 μM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting RAS/PI3K/Akt/JNK signaling cascades ^[1] .																				
In Vitro	<p>Antitumor agent-86 (0-200 μM; 48 h) dose-dependently suppresses MCF-7, MDA-MB-231, Caco-2, and PANC-1 cancer cell proliferation with IC₅₀ values of 2.617, 6.778, 14.8 and 23.58 μM, respectively^[1].</p> <p>Antitumor agent-86 (2.62 μM; 48 h) induces cell apoptosis, cell cycle arrest and decreases the levels of p-RAS proteins, mRNA transcript level of PI3K and Akt and p-JNK protein expression of MCF-7 cells^[1].</p> <p>Antitumor agent-86 (2.62 μM; 48 h) up-regulates p21 gene expression level^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7, MDA-MB-231, Caco-2 and PANC-1 cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0-200 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently suppressed cell proliferation of human cancer cell lines.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cell line</td> </tr> <tr> <td>Concentration:</td> <td>2.62 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Decreased levels of p-JNK and p-RAS in MCF-7 cells.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7 cell line</td> </tr> <tr> <td>Concentration:</td> <td>2.62 μM</td> </tr> </table>	Cell Line:	MCF-7, MDA-MB-231, Caco-2 and PANC-1 cell lines	Concentration:	0-200 μM	Incubation Time:	48 hours	Result:	Dose-dependently suppressed cell proliferation of human cancer cell lines.	Cell Line:	MCF-7 cell line	Concentration:	2.62 μM	Incubation Time:	48 hours	Result:	Decreased levels of p-JNK and p-RAS in MCF-7 cells.	Cell Line:	MCF-7 cell line	Concentration:	2.62 μM
Cell Line:	MCF-7, MDA-MB-231, Caco-2 and PANC-1 cell lines																				
Concentration:	0-200 μM																				
Incubation Time:	48 hours																				
Result:	Dose-dependently suppressed cell proliferation of human cancer cell lines.																				
Cell Line:	MCF-7 cell line																				
Concentration:	2.62 μM																				
Incubation Time:	48 hours																				
Result:	Decreased levels of p-JNK and p-RAS in MCF-7 cells.																				
Cell Line:	MCF-7 cell line																				
Concentration:	2.62 μM																				

Incubation Time:	48 hours
Result:	Induced cell apoptosis with morphological changes such as cell rounding and shrinkage with decreased cell number detachment and cytoplasmic condensation.

REFERENCES

[1]. Salem MM, et al. Synthesis, molecular docking, and in-vitro studies of pyrimidine-2-thione derivatives as antineoplastic agents via potential RAS/PI3K/Akt/JNK inhibition in breast carcinoma cells. Sci Rep. 2022 Dec 22;12(1):22146.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA